Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other financing activities (2023 - 2025)

BioXcel Therapeutics has reported Other financing activities over the past 3 years, most recently at $115000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $115000.0 for Q4 2025, down 35.75% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (up 194.3% YoY), and the annual figure for FY2025 was $1.6 million, up 239.03%.
  • Other financing activities for Q4 2025 was $115000.0 at BioXcel Therapeutics, down from $342000.0 in the prior quarter.
  • Over the last five years, Other financing activities for BTAI hit a ceiling of $803000.0 in Q1 2025 and a floor of $14000.0 in Q3 2024.
  • Median Other financing activities over the past 3 years was $149500.0 (2024), compared with a mean of $268000.0.
  • Biggest five-year swings in Other financing activities: crashed 84.17% in 2024 and later surged 2342.86% in 2025.
  • BioXcel Therapeutics' Other financing activities stood at $72000.0 in 2023, then skyrocketed by 148.61% to $179000.0 in 2024, then plummeted by 35.75% to $115000.0 in 2025.
  • The last three reported values for Other financing activities were $115000.0 (Q4 2025), $342000.0 (Q3 2025), and $135000.0 (Q2 2025) per Business Quant data.